MCC950, a specific inhibitor of NLRP3 inflammasome activation [60], has been recently used as a treatment for various NLRP3-related pathological models, including frontotemporal dementia [61], age-related metabolic syndrome [62], and obesity-induced insulin resistance [23,61]. Here, NLRP3 is linked to Insulin resistance.